Cargando…

The performance of HCV GT plus RUO reagent in determining Hepatitis C virus genotypes in Taiwan

BACKGROUND AND AIMS: Hepatitis C virus (HCV) genotyping is a pivotal tool for epidemiological investigation, guiding management and antiviral treatment. Challenge existed in identifying subtypes of genotype-1 (G-1) and genotype (GT) of indeterminate. Recently, the Abbott HCV RealTime Genotype Plus R...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Ying-Chou, Huang, Chung-Feng, Liu, Shu-Fen, Liu, Hung-Yin, Yeh, Ming-Lun, Huang, Ching-I, Hsieh, Meng-Hsuan, Dai, Chia-Yen, Chen, Shinn-Chern, Yu, Ming-Lung, Chuang, Wan-Long, Huang, Jee-Fu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7845948/ https://www.ncbi.nlm.nih.gov/pubmed/33513184 http://dx.doi.org/10.1371/journal.pone.0246376

Ejemplares similares

Nationwide registry of glecaprevir plus pibrentasvir in the treatment of HCV in Taiwan
por: Huang, Chung-Feng, et al.
Publicado: (2021)

Role of IL-28B genetic variants in HCV-related liver disease severity in patients with different viral genotypes
por: Huang, Ching-I, et al.
Publicado: (2018)

Significant amelioration of hepatitis C virus infection in a hyperendemic area: longitudinal evidence from the COMPACT Study in Taiwan
por: Tsai, Pei-Chien, et al.
Publicado: (2021)

Personalized Therapy of Chronic Hepatitis C and B Dually Infected Patients With Pegylated Interferon Plus Ribavirin: A Randomized Study
por: Yeh, Ming-Lun, et al.
Publicado: (2015)

Anti-HCV antibody titer highly predicts HCV viremia in patients with hepatitis B virus dual-infection
por: Liu, Hung-Yin, et al.
Publicado: (2021)

Cytokeratin-18 and uric acid predicts disease severity in Taiwanese nonalcoholic steatohepatitis patients
por: Huang, Jee-Fu, et al.
Publicado: (2017)

Hyperuricemia Inversely Correlates with Disease Severity in Taiwanese Nonalcoholic Steatohepatitis Patients
por: Huang, Jee-Fu, et al.
Publicado: (2015)

Huge Gap Between Clinical Efficacy and Community Effectiveness in the Treatment of Chronic Hepatitis C: A Nationwide Survey in Taiwan
por: Yu, Ming-Lung, et al.
Publicado: (2015)

Elevated on-treatment levels of serum IFN-gamma is associated with treatment failure of peginterferon plus ribavirin therapy for chronic hepatitis C
por: Lu, Ming-Ying, et al.
Publicado: (2016)

Towards a safe hospital: hepatitis C in-hospital micro-elimination program (HCV-HELP study)
por: Huang, Jee-Fu, et al.
Publicado: (2021)

Pretreatment glucose status determines HCC development in HCV patients with mild liver disease after curative antiviral therapy
por: Huang, Chung-Feng, et al.
Publicado: (2016)

Scaling up the in-hospital hepatitis C virus care cascade in Taiwan
por: Huang, Chung-Feng, et al.
Publicado: (2021)

Wisteria floribunda agglutinin-positive Mac-2-binding protein in the prediction of disease severity in chronic hepatitis B patients
por: Yeh, Ming-Lun, et al.
Publicado: (2019)

Reliable resolution of ambiguous hepatitis C virus genotype 1 results with the Abbott HCV Genotype Plus RUO assay
por: Saludes, V., et al.
Publicado: (2019)

Effectiveness and safety of 8-week glecaprevir/pibrentasvir in HCV treatment-naïve patients with compensated cirrhosis: real-world experience from Taiwan nationwide HCV registry
por: Chang, Te-Sheng, et al.
Publicado: (2023)

Orbital ordering and magnetism in layered Perovskite Ruthenate Sr(2)RuO(4)
por: Huang, Hung-Lung, et al.
Publicado: (2020)

Association of hyperuricemia with disease severity in chronic hepatitis C patients
por: Jang, Tyng-Yuan, et al.
Publicado: (2018)

A people-centered decentralized outreach model toward HCV micro-elimination in hyperendemic areas: COMPACT study in SARS Co–V2 pandemic
por: Huang, Ching-I, et al.
Publicado: (2023)

The impact of an additional extra-hepatic primary malignancy on the outcomes of patients with hepatocellular carcinoma
por: Yeh, Ming-Lun, et al.
Publicado: (2017)

Post-treatment alpha fetoprotein and platelets predict hepatocellular carcinoma development in dual-infected hepatitis B and C patients after eradication of hepatitis C
por: Yeh, Ming-Lun, et al.
Publicado: (2018)

Viral Interference Between Dengue Virus and Hepatitis C Virus Infections
por: Liang, Po-Cheng, et al.
Publicado: (2020)

Abbott RealTime HBV Assay Is More Sensitive in Detection of Low Viral Load and Little Impacted by Drug Resistant Mutation in Chronic Hepatitis B Patients under Nucleot(s)ide Analogues Therapy
por: Yeh, Ming-Lun, et al.
Publicado: (2014)

Peginterferon plus Ribavirin for HIV-infected Patients with Treatment-Naïve Acute or Chronic HCV Infection in Taiwan: A Prospective Cohort Study
por: Liu, Chen-Hua, et al.
Publicado: (2015)

Identification of groups with poor cost-effectiveness of peginterferon plus ribavirin for naïve hepatitis C patients with a real-world cohort and database
por: Tsai, Pei-Chien, et al.
Publicado: (2017)

Pegylated-Interferon Alpha Therapy for Treatment-Experienced Chronic Hepatitis B Patients
por: Yeh, Ming-Lun, et al.
Publicado: (2015)

Changing epidemiology and viral interplay of hepatitis B, C and D among injecting drug user-dominant prisoners in Taiwan
por: Lu, Ming-Ying, et al.
Publicado: (2021)

Characterization of Samples Identified as Hepatitis C Virus Genotype 1 without Subtype by Abbott RealTime HCV Genotype II Assay Using the New Abbott HCV Genotype Plus RUO Test
por: Mokhtari, Camelia, et al.
Publicado: (2016)

Therapy as prevention toward HCV elimination in maintenance hemodialysis: a multi-center, prospective cohort study
por: Huang, Chung-Feng, et al.
Publicado: (2023)

Characteristics and Survival Outcomes of Hepatocellular Carcinoma Developed after HCV SVR
por: Yeh, Ming-Lun, et al.
Publicado: (2021)

Clusters of Circulating let-7 Family Tumor Suppressors Are Associated with Clinical Characteristics of Chronic Hepatitis C
por: Tsai, Yi-Shan, et al.
Publicado: (2020)

Circulating Let-7 Family Members as Non-Invasive Biomarkers for Predicting Hepatocellular Carcinoma Risk after Antiviral Treatment among Chronic Hepatitis C Patients
por: Tsai, Yi-Shan, et al.
Publicado: (2022)

Tolloid-like 1 genetic variants determine fibrosis regression in chronic hepatitis C patients with curative antivirals
por: Huang, Chung-Feng, et al.
Publicado: (2018)

Ombitasvir/paritaprevir/ritonavir plus ribavirin for 24 weeks in patients with HCV GT4 and compensated cirrhosis (AGATE‐I Part II)
por: Asselah, Tarik, et al.
Publicado: (2019)

PNPLA3 genetic variants determine hepatic steatosis in non-obese chronic hepatitis C patients
por: Huang, Chung-Feng, et al.
Publicado: (2015)

Equal treatment efficacy of direct-acting antivirals in patients with chronic hepatitis C and hepatocellular carcinoma? A prospective cohort study
por: Huang, Chung-Feng, et al.
Publicado: (2019)

Long-Term Effect of Interferon Plus Ribavirin on Hepatitis B Surface Antigen Seroclearance in Patients Dually Infected with Hepatitis B and C Viruses
por: Yeh, Ming-Lun, et al.
Publicado: (2011)

The Cost-Effectiveness Analysis of Transplant-Ineligible Myeloma Patients with Bortezomib plus Thalidomide plus Dexamethasone (VTD) or Bortezomib plus Melphalan plus Prednisolone (VMP) Treatment in Southern Taiwan
por: Du, Jeng-Shiun, et al.
Publicado: (2022)

Virological Predictors of Response to Retreatment in Hepatitis C Genotype 2 Infected Patients
por: Huang, Chung-Feng, et al.
Publicado: (2013)

Four weeks of paritaprevir/ritonavir/ombitasvir plus dasabuvir encountering dengue fever resulted in sustained virological response in an HCV patient: A case report
por: Huang, Chung-Feng, et al.
Publicado: (2016)

The Prevalence and Serological Association of Hepatitis D Virus Genotypes in Taiwan
por: Joseph, Keva, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ojedc9d983opn95idiv5dnkr39